QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
NASDAQ:BIOR

Biora Therapeutics (BIOR) Stock Price, News & Analysis

$1.11
-0.06 (-5.14%)
(As of 12:46 PM ET)
Today's Range
$1.08
$1.17
50-Day Range
$0.81
$1.54
52-Week Range
$0.76
$6.70
Volume
201,180 shs
Average Volume
383,244 shs
Market Capitalization
$30.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Biora Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Biora Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.06) to ($2.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.81 out of 5 stars

Medical Sector

838th out of 939 stocks

Pharmaceutical Preparations Industry

386th out of 433 stocks

BIOR stock logo

About Biora Therapeutics Stock (NASDAQ:BIOR)

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

BIOR Stock Price History

BIOR Stock News Headlines

BIOR: Negotiations Accelerating
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Biora Therapeutics: Q4 Earnings Insights
Q4 2023 Biora Therapeutics Inc Earnings Call
Here's what Wall Street expects from Biora Therapeutics's earnings
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Biora Therapeutics (BIOR) Scheduled to Post Earnings on Tuesday
BIOR Jul 2024 4.000 call
BIOR Apr 2024 2.500 put
BIOR Apr 2024 1.000 put
BIOR Oct 2024 2.000 call
BIOR Oct 2024 4.000 put
Biora Therapeutics Inc Ordinary Shares BIOR
BIOR Mar 2024 1.000 call
Biora Therapeutics Inc Ordinary Shares
See More Headlines
Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BIOR
Fax
N/A
Employees
54
Year Founded
N/A

Profitability

Net Income
$-38,160,000.00
Net Margins
-55,269.39%
Pretax Margin
-677,261.06%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($11.46) per share

Miscellaneous

Free Float
20,902,000
Market Cap
$31.84 million
Optionable
Optionable
Beta
1.11
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Aditya P. Mohanty M.B.A. (Age 57)
    CEO & Director
    Comp: $858.82k
  • Mr. Eric d'Esparbes (Age 56)
    Executive VP & CFO
    Comp: $651.91k
  • Mr. Clarke Neumann J.D. (Age 60)
    Senior VP, General Counsel & Secretary
    Comp: $624.13k
  • Eric Fox
    VP of Finance & Accounting & Treasurer
  • Mr. Troy Seelye (Age 60)
    Chief Information Officer
  • Mr. George Gianakopoulos (Age 63)
    Senior Vice President of Sales
  • Ms. Robyn Hatton
    Head of Human Resources
  • Mr. Kevin Howe Ph.D.
    Senior VP of Strategic Operations
  • Dr. Sharat Singh Ph.D. (Age 65)
    Head of Research
  • Dr. Paul Shabram M.B.A.
    Head of Technical Operations

BIOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Biora Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares.
View BIOR analyst ratings
or view top-rated stocks.

How have BIOR shares performed in 2024?

Biora Therapeutics' stock was trading at $1.35 at the beginning of 2024. Since then, BIOR shares have decreased by 18.1% and is now trading at $1.1050.
View the best growth stocks for 2024 here
.

When is Biora Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our BIOR earnings forecast
.

How were Biora Therapeutics' earnings last quarter?

Biora Therapeutics, Inc. (NASDAQ:BIOR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.01. The business earned $0.18 million during the quarter, compared to analysts' expectations of $11.10 million. During the same quarter in the prior year, the firm earned ($1.01) earnings per share.

When did Biora Therapeutics' stock split?

Biora Therapeutics's stock reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Biora Therapeutics' major shareholders?

Biora Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.87%), Vanguard Group Inc. (1.87%), Virtu Financial LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L and Surbhi Sarna.
View institutional ownership trends
.

How do I buy shares of Biora Therapeutics?

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIOR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners